ABSTRACT
Background Interstitial lung disease (ILD) is a known complication of rheumatoid arthritis (RA) with a lifetime risk in any individual of 7.7%. The TRAIL1 trial was a randomized, double-blinded, placebo-controlled, phase 2 study of safety, tolerability, and efficacy of pirfenidone for the treatment of patients with RA-ILD.
Methods The TRAIL1 was a phase 2 trial intended to enroll 270 adult patients (18 to 85 years) with established RA-ILD at 33 sites in 4 countries. Patients were randomly assigned (1:1) to 2,403 mg oral pirfenidone or placebo daily. The primary endpoint was the incidence of the composite endpoint of decline from baseline in percent predicted forced vital capacity (FVC%) of 10% or greater or death during the 52-week treatment period. Key secondary endpoints included change in absolute and FVC% over 52 weeks.
Findings The trial was stopped early due to slow recruitment and soon after the shutdown of clinical trials as a consequence of the coronavirus disease 2019 (COVID-19) pandemic. Data from 123 patients enrolled were analyzed. The primary endpoint was met by 11.1% on pirfenidone vs. 15% on placebo [OR=0.67 (0.22, 2.03), p=0.48]. Subjects receiving pirfenidone had a slower rate of decline in lung function as measured by estimated annual change in FVC(ml) (−66 vs. -146, p=0.0082) and FVC(%) (−1.02 vs. -3.21, p=0.0028). This effect on decline was also seen when analyzed within participants with baseline usual interstitial pneumonia (UIP) pattern on HRCT (FVC(ml) (−43 vs. -169, p=0.0014) and FVC% (−0.2 vs. -3.81, p=0.0002)). There was no significant difference in the rate of treatment-emergent serious adverse events.
Interpretation Due to early termination of the study, results should be interpreted with caution. Despite being underpowered to evaluate the primary endpoint, pirfenidone slowed the rate of decline of FVC over time in subjects with RA-ILD. Safety in patients with RA-ILD was similar to that seen in other pirfenidone trials.
Funding Funding for this investigator initiated trial was provided by Genentech, Inc. to Ivan O. Rosas, MD, on behalf of the TRAIL1 Investigators.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02808871
Clinical Protocols
https://www.clinicaltrials.gov
Funding Statement
This study received funding from Genentech
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Brigham and Womens Hospital gave ethical approval as primary site 2017PO00062PHS Baylor College of Medicine gave ethical approval Cleveland Clinic gave ethical approval Johns Hopkins Hospital gave ethical approval Mayo Clinic Rochester gave ethical approval National Jewish Health gave ethical approval Tulane University gave ethical approval University of Alabama Birmingham gave ethical approval University of Miami gave ethical approval University of Michigan gave ethical approval University of San Francisco gave ethical approval University of Utah gave ethical approval University of Washington gave ethical approval Vanderbilt University gave ethical approval Weill Cornell Medicine gave ethical approval McMaster University gave ethical approval University of British Columbia gave ethical approval University of Calgary gave ethical approval University of Toronto gave ethical approval Glenfield Hospital Leicester gave ethical approval Norfolk and Norwich University Hospital gave ethical approval North Bristol NHS Trust gave ethical approval Oxford University Hospitals gave ethical approval Royal Brompton Hospital gave ethical approval Royal Devon and Exeter Hospital gave ethical approval Royal Edward Infirmary gave ethical approval Royal Papworth Hospital gave ethical approval Royal Victoria Infirmary, Newcastle upon Tyne, gave ethical approval Southampton General Hospital gave ethical approval St James University Hospital gave ethical approval University Hospital Aintree gave ethical approval Wythenshawe Hospital gave ethical approval Alfred Health gave ethical approval Royal Prince Alfred Hospital gave ethical approval The Prince Charles Hospital The University of Queensland gave ethical approval
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ Co-senior
** TRAIL1 study group members listed in the Appendix.
Data Availability
TRAIL1 network will share de-identified study information to approved investigators
